As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Diacerein 1% did not outperform vehicle in study ...
FDA-approved EB therapies expand options for gene replacement and wound healing, but success depends on careful wound preparation and timing, experts say.
The patient has the Hallopeau-Siemens variant of dystrophic epidermolysis bullosa (EB). EB comprises a group of rare genetic states that are characterized by extremely fragile skin and recurrent ...
The four main types of epidermolysis bullosa (EB): dystrophic epidermolysis bullosa (DEB), epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS) are ...
ROOTSTOWN, Ohio, January 06, 2026--(BUSINESS WIRE)--As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results